MedTrace Logo

Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B

NCT02844491 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2021-02-02

No results posted yet for this study

Summary

Cancer-specific splice variants gain significant interest as they generate neo-antigens, that could be targeted by immune cells. CD20, a membrane antigen broadly expressed in mature B cell lymphomas, is subject to an alternative splicing named Delta-CD20 leading to loss of membrane expression of the spliced isoform.

The investigators group would now determine if it's possible, in patients with lymphoproliferative B, to detect the presence of a specific memory response to delta-CD20 peptides.

If this memory response exists, it will confirm the interest of this antigen as a target for tumor immunotherapy.

Conditions

  • Hematological Malignancies B

Interventions

OTHER

additional biological samples

blood and tissue samples

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-22
Primary Completion
2014-09-19
Completion
2014-09-19

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02844491 on ClinicalTrials.gov